Naudingos nuorodos
Information for Marketing authorisation holders

To assess the likelihood of a potential drug supply disruption related to coronavirus infection, the Agency is asking all marketing authorisation holders whose active substances are manufactured in China inform the Agency of any unexpected disruption of the active substances due to the named reason. Information should be send by e-mail until 17th of February 2020.